Discover
AVTX
Avalo Therapeutics, Inc.
19.84
1 x 19.79
5 x 19.88
bid
ask
+
0.07
0.33%
01:26 PM
timesize
| Ytd | 9.22% | |
| 1y | 120.14% |
18.87
day range
19.98
8.41
52 week range
24.27
| Open | 19.98 | Prev Close | 19.77 | Low | 18.87 | High | 19.98 | Mkt Cap | 1.04B |
| Vol | 385.88K | Avg Vol | 1.48M | EPS | -4.37 | P/E | -4.54 | Forward P/E | -6.95 |
| Beta | 0.80 | Short Ratio | 5.86 | Inst. Own | 75.28% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 17.31 | 200-d Avg | 16.62 | 1yr Est | 44.69 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-05 | 2026-09 | -0.6 | N/A | N/A | N/A |
| 2026-08-06 | 2026-06 | -0.58 | -0.83 | -0.25 | -42.43% |
| 2026-05-13 | 2026-03 | -1 | -0.98 | 0.02 | 2.00% |
| 2026-03-23 | 2025-12 | -1.54 | -0.37 | 1.17 | 75.97% |
| 2025-11-06 | 2025-09 | -1.67 | -2.19 | -0.52 | -31.14% |
| 2025-08-07 | 2025-06 | -1.43 | -1.92 | -0.49 | -34.27% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-08-07 | Guggenheim | Upgrade | Buy | Buy |
| 2026-08-07 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-07-06 | Leerink Partners | Upgrade | Outperform | |
| 2026-06-16 | BTIG | Upgrade | Buy | Buy |
| 2026-06-12 | B of A Securities | Upgrade | Buy | |
| 2026-05-14 | Citizens | Upgrade | Market Outperform | Market Outperform |
Profile
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2025-03-27 | ALMENOFF JUNE SHERIE | Director | 4.17K | Conversion of Exercise of derivative security |
| 2026-07-26 | DOYLE MITTIE | Officer | 51.78K | Conversion of Exercise of derivative security |
| 2026-03-26 | GOLDMAN JONATHAN | Director | 3.17K | Conversion of Exercise of derivative security |
| 2026-03-26 | KANTOFF AARON | Director | 6.33K | Conversion of Exercise of derivative security |
| 2026-03-26 | KAPLAN GILLA | Director | 6.33K | Conversion of Exercise of derivative security |
| 2026-05-20 | NEIL GARRY A. M.D. | Chief Executive Officer | 190.31K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Blackrock Inc. | 4.37M | 86.31M | 8.14% |
| 2026-06-29 | State Street Corporation | 2.89M | 57.12M | 5.39% |
| 2026-03-30 | FMR, LLC | 2.88M | 56.93M | 5.37% |
| 2026-03-30 | T. Rowe Price Investment Management, Inc. | 2.16M | 42.76M | 4.03% |
| 2026-03-30 | Caligan Partners, LP | 1.64M | 32.32M | 3.05% |
| 2026-03-30 | BVF Inc. | 1.63M | 32.28M | 3.04% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.02M | 39.97M | 3.77% |
| 2026-06-29 | iShares Trust-iShares Russell 2000 ETF | 1.10M | 21.74M | 2.05% |
| 2026-05-30 | Fidelity Capital Trust-Fidelity Stock Selector Small Cap Fund | 924.30K | 18.27M | 1.72% |
| 2026-03-30 | T. Rowe Price Small-Cap Stock Fund, Inc. | 678.82K | 13.42M | 1.27% |
| 2026-05-30 | Fidelity Securities Fund-Fidelity Series Small Cap Opportunities Fund | 658.50K | 13.02M | 1.23% |
| 2026-06-29 | Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 639.70K | 12.65M | 1.19% |
Split
| Split | Date |
|---|---|
| 1 : 239 | 2023-12-29 |
| 1 : 12 | 2022-07-08 |